Phase II
Data security risks are growing as more and more clinical trials embrace telemedicine and other digital technologies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.
In June, it dosed its first two patients using a novel therapeutic, AMT-130, delivered directly to the brain. Initial readouts are expected in a year’s time.
New York-based Immunic reported positive topline data from its Phase II EMPhASIS trial of IMU-838 in relapsing-remitting multiple sclerosis (RRMS).
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.
As usual, there was plenty of clinical trial news last week. Here’s a look.
In October 2019, Alexion Pharmaceuticals snapped up Achillon Pharmaceuticals and its oral small molecule Factor D inhibitor program for a rare kidney disease for $930 million in cash. This week, the company shuttered the program following disappointing clinical data.
AiCure’s phone app helps clinical trials keep tabs on which participants have taken their medications correctly and which have not. By analyzing videos the app takes, they can also spot who is intentionally not taking their pills, known as intentional nonadherence.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 31, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
PRESS RELEASES